We want to improve the outlook of early breast cancer patients by reducing the risk of relapse and increasing their chances of survival. So every patient can live a better life, with better insight on their future.
For a brighter outlook on life.
We are offering a biomarker test that easily provides objective information of a patient’s prognosis.
The test to progress precision medicine.
Our published data enables a new perspective on the influence of the MAF gene in bisphosphonates treatment outcome, enabling more personal treatment plans.
Prof Rob E. Coleman
MD, MBBS, FRCP, FRCPE · Chairman
Dr. Coleman is Emeritus Professor of Medical Oncology at Weston Park Hospital and the University of Sheffield, UK. Dr. Coleman has been instrumental in developing clinical cancer research and in establishing an internationally respected bone oncology research team in Sheffield. Dr. Coleman has held many leadership roles within the university and the UK National Institute for Health Research (NIHR) Cancer Research Network. Dr. Coleman has developed a highly successful cancer clinical trials facility, which has both led and participated in a broad range of clinical trials-ranging from early phase drug development studies to large phase III randomised trials. In 2020, Dr. Colemen and co-workers published the ESMO Clinical Practice Guidelines for bone health in cancer.
Dr. Hayes is the Stuart B. Padnos Professor of Breast Cancer Research.at the University of Michigan Rogel Cancer Center. He chairs, or has chaired, several national and international scientific committees, including the Breast Cancer Translational Medicine subcommittee of SWOG, in which he mentored young investigators from other centers. He was the inaugural recipient of the American Society of Clinical Oncology (ASCO) Gianni Bonadonna Breast Cancer Award (2007), given for achievement in translational research and mentoring, and has held many leadership roles in ASCO, including a three-year Presidential term of office (2015-2018). He is a Fellow of ASCO, a Fellow of the American College of Physicians, a Komen Scholar, and a member of the Association of American Physicians and the American Clinical and Climatologic Association.
Expertise:
bone oncology, breast cancer,
clinical cancer research, clinical trials
Expertise:
breast cancer, clinical biomarker validation, clinical trials, personalized medicine
MD
Scientific and clinical advisory board
MD
MD
Expertise:
breast cancer, TNBC, clinical trials, translational research, clinical oncology
Expertise:
breast cancer, clinical trials, medical oncology
Dr. Coleman is Emeritus Professor of Medical Oncology at Weston Park Hospital and the University of Sheffield, UK. Dr. Coleman has been instrumental in developing clinical cancer research and in establishing an internationally respected bone oncology research team in Sheffield. Dr. Coleman has held many leadership roles within the university and the UK National Institute for Health Research (NIHR) Cancer Research Network. Dr. Coleman has developed a highly successful cancer clinical trials facility, which has both led and participated in a broad range of clinical trials-ranging from early phase drug development studies to large phase III randomised trials. In 2020, Dr. Colemen and co-workers published the ESMO Clinical Practice Guidelines for bone health in cancer.
Professor Albanell is the head of the medical oncology department at Hospital del Mar in Barcelona. He
is a founding member of GEICAM (Spanish Group of Breast Cancer Research), coordinator of the group
transGEICAM and member of the board of directors of SEOM (Spanish Society of Medical Oncology).
Since
2007, he has been directing the Cancer Research Programme at the Hospital del Mar Medical Research
Institute. He is a Professor of Oncology at Pompeu Fabra University and coordinates HM CIOCC in
Barcelona.
Board of directors and management
Towards a future in which breast cancer is no longer a life-threatening disease.
in.bio.motion.
We provide a test that generates objective insights into whether a patient has above-normal levels of the MAF gene.
In doing so, we enable pathologists with a new tool for oncologists expanding their possibilities to treat patients effectively and efficiently with bisphosphonates while minimising the possible risk of a relapse in the future.
Our dedication and drive to generate clinical results, offers a new proven perspective that will progress precision medicine today.
Together, we will drive new perspectives towards a future where breast cancer is no longer a life-threatening disease.
